Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accumulated Expenses: 2022-2024

Historic Accumulated Expenses for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $18.6 million.

  • Stoke Therapeutics' Accumulated Expenses rose 90.85% to $30.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year increase of 90.85%. This contributed to the annual value of $18.6 million for FY2024, which is 34.40% up from last year.
  • As of FY2024, Stoke Therapeutics' Accumulated Expenses stood at $18.6 million, which was up 34.40% from $13.8 million recorded in FY2023.
  • In the past 5 years, Stoke Therapeutics' Accumulated Expenses ranged from a high of $18.6 million in FY2024 and a low of $13.8 million during FY2023.
  • Its 3-year average for Accumulated Expenses is $16.0 million, with a median of $15.7 million in 2022.
  • As far as peak fluctuations go, Stoke Therapeutics' Accumulated Expenses declined by 12.27% in 2023, and later soared by 34.40% in 2024.
  • Over the past 3 years, Stoke Therapeutics' Accumulated Expenses (Yearly) stood at $15.7 million in 2022, then dropped by 12.27% to $13.8 million in 2023, then surged by 34.40% to $18.6 million in 2024.